Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL)
Cancer Research and Treatment. 2021;53(3):695-702 
Re: Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study
European Journal of Cancer. 2022;171:43
Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients
Breast Cancer Research and Treatment. 2019;179(2):371-376
Palbociclib or Ribociclib in First-Line Treatment in Patients With Hormone Receptor–Positive/Human Epidermal Receptor 2–Negative Advanced or Metastatic Breast Cancer? A Perspective Based on Pharmacologic Costs
Clinical Breast Cancer. 2019;19(4):e519-e521
Effectiveness of Palbociclib in Combination with Fulvestrant in Patients with Advanced or Metastatic, Hormone Receptor Positive, Her2-Negative Breast Cancer: a Real-World Study from Colombia
. 2022;
Patient-reported outcomes of palbociclib plus exemestane with GnRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer from the YoungPearl phase ll trial (KCSG-BR 15-10, NCT02592746)
Annals of Oncology. 2019;30:v862
Adjuvant Systemic Treatment in Hormone Receptor Positive, HER2 Negative Breast Cancer
Breast Cancer and Surgery. 2018;
Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): subgroup analysis of 2 randomized phase 3 studies
The Breast. 2018;41:S11-S12
Real-World Experience of Palbociclib-Induced Adverse Events and Compliance With Complete Blood Count Monitoring in Women With Hormone Receptor–Positive/HER2-Negative Metastatic Breast Cancer
Clinical Breast Cancer. 2019;19(1):e186-e194
Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer
Breast Cancer Research and Treatment. 2019;175(3):775-779